uTREAT®

Curasight's primary focus is to advance uTREAT® - a first-in-class radioligand therapy platform targeting uPAR – the functional driver of cancer aggressiveness across solid tumors. It is designed to eliminate aggressive cancer cells across multiple tumor types, including minimal residual disease, micro-metastases, and other lesions distant from the primary tumor. uTREAT®, is supported by uTRACE®, our clinically validated uPAR PET diagnostic platform built on the same uPAR-targeting ligand.

The advantage of targeted radiation therapy instead of external radiation therapy
The principle and advantage of using targeted radioligand therapy (RLT) rather than conventional external beam radiation therapy is that RLT binds primarily to uPAR-expressing tumor tissue, enabling localized radiation delivery to uPAR-positive lesions, including small metastases, while minimizing irradiation of healthy tissue. External radiation therapy irradiates the primary tumor and only a limited number of lesions from the outside, and significantly irradiates healthy tissue, thereby causing side effects and chronic damage.

Using peptide as the ligand rather than antibodies

uTREAT® is based on a small uPAR-binding peptide. The advantage is that peptides have a very short lifespan in the blood (less than ten minutes), meaning that uTREAT® that is not bound to tumor target is quickly eliminated from the body. If antibodies are used, they remain in circulation for days, causing substantial and continued irradiation of healthy tissue.